کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
4499986 1624018 2015 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
An analysis of strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia with imatinib-resistant mutations
ترجمه فارسی عنوان
تجزیه و تحلیل اختلالات استراتژیک درمان در طول درمان با امیتینیب از لوسمی مزمن میلوئیدی با جهش های مقاوم به ایماتینیب
کلمات کلیدی
مدل سازی ریاضی، معادلات دیفرانسیل تأخیر، لوسمی مزمن میلوئیدی، اختلالات درمان استراتژیک، زیست شناسی ریاضی
موضوعات مرتبط
علوم زیستی و بیوفناوری علوم کشاورزی و بیولوژیک علوم کشاورزی و بیولوژیک (عمومی)
چکیده انگلیسی


• We study resistance in a DDE mathematical model of imatinib treatment CML.
• We derive values of patient-dependent parameters in the case of resistance.
• We simulate strategic treatment interruptions during imatinib treatment of CML.
• We study the sensitivity of the STI results to the parameter values.

Chronic myelogenous leukemia (CML) is a cancer of the white blood cells that results from increased and uncontrolled growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. The most common form of treatment for CML is imatinib, a tyrosine kinase inhibitor. Although imatinib is an effective treatment for CML and most patients treated with imatinib do attain some form of remission, imatinib does not completely eradicate all leukemia cells, and if treatment is stopped, all patients eventually relapse (Cortes, 2005). In Kim (2008), the authors developed a mathematical model for the dynamics of CML under imatinib treatment that incorporates the anti-leukemia immune response, and in Paquin (2011), the authors used this mathematical model to study strategic treatment interruptions as a potential therapeutic strategy for CML patients. Although the authors presented the results of several numerical simulations in Paquin (2011), the studies in that work did not include the possibility of imatinib-resistant mutations or an initial population of imatinib-resistant leukemia cells. As resistance is a significant consideration in any drug treatment, it is important to study the efficacy of the strategic treatment interruption plan in the presence of imatinib resistance. In this work, we modify the delay differential equations model of Kim (2008), Paquin (2011) to include the possibility of imatinib resistance, and we analyze strategic treatment interruptions as a potential therapeutic tool in the case of patients with imatinib-resistance leukemia cells.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Mathematical Biosciences - Volume 262, April 2015, Pages 117–124
نویسندگان
, , ,